Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.97 USD | -4.12% | -3.35% | -64.34% |
Apr. 30 | Medifast Shares Drop as Q1 Adjusted Earnings, Revenue Decline; Sets Q2 Guidance | MT |
Apr. 30 | Wall Street Poised for Cautious Day Ahead of Key Numbers, Earnings, Fed Report | MT |
Summary
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The company shows low valuation levels, with an enterprise value at 0.14 times its sales.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
- The company benefits from high valuations in earnings multiples.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-64.34% | 267M | C- | ||
+4.94% | 7.74B | C- | ||
+2.93% | 5.92B | - | ||
-5.18% | 3.77B | B- | ||
-11.51% | 3.52B | D | ||
-12.06% | 1.23B | - | - | |
-28.83% | 1.04B | B+ | ||
+15.98% | 988M | - | ||
-8.82% | 929M | C+ | ||
-14.37% | 823M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MED Stock
- Ratings Medifast, Inc.